Wire · regulatory
Capricor Plunges On Regulatory Setback As FDA Declines To Approve Deramiocel For Duchenne
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 November 2026 · Fusion42 review
The FDA has declined to approve Capricor's cell therapy drug Deramiocel for treating Duchenne muscular dystrophy, causing a significant drop in the company's stock value.
This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 12 Nov 2026 and 21 Nov 2026.
◆ ◆ The Wire takeaway
You face increased risk entering clinical-stage biotech with FDA setbacks like Capricor's Deramiocel. Re-evaluate your trial design and regulatory strategy now to avoid similar delays.
◆ Coverage
4 sources · first reported 12 Nov 2026 · latest 21 Nov 2026
◆ Related on Wire
◆ Topics